



FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/821,809	ATTY. DOCKET NO.: P0453.70116US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: April 8, 2004	CONFIRMATION NO.: Not Yet Assigned
		APPLICANT: Sanghvi et al.	
		GROUP ART UNIT: 1614	EXAMINER: SPIVACK
Sheet	1	of	6

#### U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
PS	A1	2001/0018413	A1	Crain, et al.	08-30-2001
	A2	2002/0028825	A1	Foss, et al.	03-07-2002
	A3	2001/0033865	A1	Oshlack, et al.	10-25-2001
	A4	2001/0036476	A1	Oshlack, et al.	11-01-2001
	A5	2001/0047005	A1	Farrar, et al.	11-29-2001
	A6	4,176,186		Goldberg, et al.	11-27-1979
	A7	4,719,215		Goldberg	01-12-1988
	A8	4,861,781		Goldberg	08-29-1989
	A9	4,987,136		Kreek, et al.	01-22-1991
	A10	5,102,887		Goldberg	04-07-1992
	A11	5,270,328		Cantrell, et al.	12-14-1993
	A12	5,472,943		Crain, et al.	12-05-1995
	A13	5,512,578		Crain, et al.	04-30-1996
	A14	5,767,125		Crain, et al.	06-16-1998
	A15	5,811,451		Minoia, et al.	09-22-1998
	A16	5,866,164		Kuczynski, et al.	02-02-1999
	A17	5,958,452		Oshlack, et al.	09-28-1999
	A18	5,972,954		Foss, et al.	10-26-1999
	A19	6,096,756		Crain, et al.	08-01-2000
	A20	6,194,382	B1	Crain, et al.	02-27-2001
	A21	6,261,599	B1	Oshlack, et al.	07-17-2001
	A22	6,274,591	B1	Foss, et al.	08-14-2001
	A23	6,395,705	B2	Crain, et al.	05-28-2002
	A24	6,419,959	B1	Walter, et al.	07-16-2002
	A25	6,451,806	B2	Farrar	09-17-2002
	A26	6,559,158	B1	Foss, et al.	05-06-2003
	A27	6,608,075	B1	Foss, et al.	08-19-2003
	A28	RE36,547		Crain, et al.	02-01-2000
	A29	2002/0188005	A1	Farrar, et al.	12-12-2002

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
PS	B1	AU	610,561		Shelley	08-17-1988	
PS	B2	CA	1,315,689		The University of Chicago	04-06-1993	
PS	B3	EP	0278821	A1	Shelly (Abstract)	08-17-1988	

Phyllis Spivack 5/27/07

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/821,809		ATTY. DOCKET NO.: P0453.70116US01	
				FILING DATE: April 8, 2004		CONFIRMATION NO.: Not Yet Assigned	
				APPLICANT: Sanghvi et al.			
				GROUP ART UNIT: Not Yet Assigned		EXAMINER: Not Yet Assigned	
Sheet	2	of	6				

PS	B4	EP	0352361	A1	The Rockefeller University	01-31-1990	
PS	B5	EP	278,821	A1	Marc Yves Shelly (Derwent Abstract)	08-17-1988	
PS	B6	EP	306,575	B1	The Univ. of Chicago	03-15-1989	
PS	B7	EP	352,361	A1	The Rockefeller University	01-31-1990	
PS	B8	EP	760,661	B1	Minoia, et al.	12-30-1998	
PS	B9	JP	2,625,457	B2	Goldberg (Derwent Abstract)	07-02-1997	
PS	B10	NZ	222,911		The Univ. of Chicago	12-14-1987	
PS	B11	WO	83/03197	A1	The Rockefeller University	09-29-1983	
PS	B12	WO	88/05297	A1	Shelly	07-28-1988	
PS	B13	WO	95/31985	A2	Minoia, et al.	11-30-1995	
PS	B14	WO	97/33566		Alza Corp.	09-18-1997	
PS	B15	WO	98/25613		Klinge Pharma GmbH	06-18-1998	Yes
PS	B16	WO	01/13909	A2	Critical Care Pharm.	03-01-2001	
PS	B17	WO	01/37785	A2	Adolor Corp.	05-31-2001	
PS	B18	WO	01/41705	A2	Adolor Corp.	06-14-2001	
PS	B19	WO	01/42207	A2	Adolor Corp.	06-14-2001	
PS	B20	WO	01/85257	A2	Pain Therapeutics, Inc..	11-15-2001	
PS	B21	WO	02/060870	A2	Adolor Corp.	08-08-2002	

# OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
PS	C1	AKINBAMI et al., Effect of a peripheral and a central acting opioid antagonist on the testicular response to stress in rats. Neuroendocrinology. 1994 Apr;59(4):343-8.	
PS	C2	AMIN et al., Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response. Anesth Analg. 1994 Apr;78(4):701-5.	
PS	C3	AMIR, Naloxone improves, and morphine exacerbates, experimental shock induced by release of endogenous histamine by compound 48/80. Brain Res. 1984 Apr 9;297(1):187-90.	
PS	C4	AMIR et al., Endorphins in endotoxin-induced hyperglycemia in mice. Arch Toxicol Suppl. 1983;6:261-5.	
PS	C5	ARGENTIERI et al., Interaction of the opiate antagonist, naltrexone methyl bromide, with the acetylcholine receptor system of the motor end-plate. Brain Res. 1983 Oct 31;277(2):377-9.	
PS	C6	BARATTI et al., Brain opioid peptides may participate in the reversal of pentylenetetrazol-induced amnesia. Methods Find Exp Clin Pharmacol. 1990 Sep;12(7):451-6.	
PS	C7	BEDINGFIELD et al., Methylnaltrexone attenuates taste aversion conditioned by low-dose ethanol. Alcohol. 1998 Jan;15(1):51-4.	
PS	C8	BIANCHETTI et al., Quaternary derivatives of narcotic antagonists: stereochemical requirements at the chiral nitrogen for in vitro and in vivo activity. Life Sci. 1983;33 Suppl 1:415-8.	
PS	C9	BIANCHI et al., Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity. Life Sci. 1982 May 31;30(22):1875-83.	
PS	C10	BICKEL, Stimulation of colonic motility in dogs and rats by an enkephalin analogue pentapeptide. Life Sci. 1983;33 Suppl 1:469-72.	
PS	C11	BLANK et al., Central, stereoselective receptors mediate the acute effects of opiate antagonists on luteinizing hormone secretion. Life Sci. 1986 Oct 27;39(17):1493-99.	
PS	C12	BRIX-CHRISTENSEN et al., Endogenous morphine is produced in response to cardiopulmonary bypass in neonatal pigs. Acta Anaesthesiol Scand. 2000 Nov;44(10):1204-8.	
PS	C13	BROWN et al., Opiate antagonists: central sites of action in suppressing water intake of the rat. Brain Res. 1981, Sep 28;221(2):432-6.	

Phyllis Spwack 5/27/07

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/821,809	ATTY. DOCKET NO.: P0453.70116US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: April 8, 2004	CONFIRMATION NO.: Not Yet Assigned
		APPLICANT: Sanghvi et al.	
		GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned
Sheet	3	of	6

PS	C14	BROWN et al., Reversal of morphine-induced catalepsy in the rat by narcotic antagonists and their quaternary derivatives. Neuropharmacology. 1983 Mar;22(3):317-21.		
PS	C15	BROWN et al., The use of quaternary narcotic antagonists in opiate research. Neuropharmacology. 1985 Mar;24(3):181-91. Review.		
PS	C16	CALCAGNETTI et al., Quaternary naltrexone reveals the central mediation of conditional opioid analgesia. Pharmacol Biochem Behav. 1987 Jul;27(3):529-31.		
PS	C17	CHANG et al., An antiabsorptive basis for precipitated withdrawal diarrhea in morphine-dependent rats. J Pharmacol Exp Ther. 1984 Feb;228(2):364-9.		
PS	C18	CULPEPPER-MORGAN et al., Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther. 1992 Jul;52(1):90-5 (ABSTRACT ONLY).		
PS	C19	EISENBERG, Effects of naltrexone on plasma corticosterone in opiate-naive rats: a central action. Life Sci. 1984 Mar 19;34(12):1185-91.		
PS	C20	FERNANDEZ-TOME et al., Interaction between opioid agonists or naloxone and 5-HTP on feeding behavior in food-deprived rats. Pharmacol Biochem Behav. 1988 Feb;29(2):387-92.		
PS	C21	FOSS, A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg. 2001 Nov;182(5A Suppl):19S-26S. Review.		
PS	C22	FOSS et al., 1995 Annual scientific meeting of the American Society of Anesthesiologists. Atlanta, Georgia, October 21-25, 1995. Abstracts. Anesthesiology. 1995 Sep;83(3A Suppl):A361.		
PS	C23	FOSS et al., Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother Pharmacol. 1998;42(4):287-91.		
PS	C24	FOSS et al., Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol. 1997 Jan;37(1):25-30.		
PS	C25	FOSS et al., Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J Clin Pharmacol. 1993 Aug;33(8):747-51.		
PS	C26	FOSS et al., Effects of methylnaltrexone on morphine-induced cough suppression in guinea pigs. Life Sci. 1996;59(15):PL235-8.		
PS	C27	FOSS et al., Methylnaltrexone reduces morphine-induced postoperative emesis by 30%. Anesth Analg. 1994;78:S119.		
PS	C28	FRANCE et al., Comparison of naltrexone and quaternary naltrexone after systemic and intracerebroventricular administration in pigeons. Neuropharmacology. 1987 Jun;26(6):541-8.		
PS	C29	FRANCE et al., Intracerebroventricular drug administration in pigeons. Pharmacol Biochem Behav. 1985 Nov;23(5):731-6.		
PS	C30	FRIEDMAN et al., Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother. 2001 Jan;35(1):85-91. Review.		
PS	C31	GMEREK et al., Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharmacol Exp Ther. 1986 Jan;236(1):8-13.		
PS	C32	HEIN et al., Pharmacological analysis of the discriminative stimulus characteristics of ethylketazocine in the rhesus monkey. J Pharmacol Exp Ther. 1981 Jul;218(1):7-15.		
PS	C33	HOWD et al., Naloxone and intestinal motility. Experientia. 1978 Oct 15;34(10):1310-1.		
PS	C34	JALOWIEC et al., Suppression of juvenile social behavior requires antagonism of central opioid systems. Pharmacol Biochem Behav. 1989 Jul;33(3):697-700.		
PS	C35	JANKOVIC et al., Quaternary naltrexone: its immunomodulatory activity and interaction with brain delta and kappa opioid receptors. Immunopharmacology. 1994 Sep-Oct;28(2):105-12.		
PS	C36	KAUFMAN et al., Role of opiate receptors in the regulation of colonic transit. Gastroenterology. 1988 Jun;94(6):1351-6.		
PS	C37	KIM et al., Assay for methylnaltrexone in rat brain regions and serum by high-performance liquid chromatography with coulometric electrochemical detection. Chromatographia. 1989 Oct;28(7-8):359-63.		
PS	C38	KINSMAN et al., Effect of naloxone on feedback regulation of small bowel transit by fat. Gastroenterology. 1984 Aug;87(2):335-7.		
PS	C39	KOBLISH et al., Behavioral profile of ADL 8-2698, a novel GI-restricted $\mu$ opioid receptor antagonist. Society for Neuroscience Abstracts. 2001;27(2):2407.		
PS	C40	KOBYLECKI et al., N-Methylnalorphine: definition of N-allyl conformation for antagonism at the opiate receptor. J Med Chem. 1982 Nov;25(11):1278-80.		
PS	C41	KOCZKA, et al., Acta Chimica Academica Scien. Hung. (1967) 51(4), 393-02.		

Phyllis Spivack 5/27/07

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/821,809	ATTY. DOCKET NO.: P0453.70116US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: April 8, 2004	CONFIRMATION NO.: Not Yet Assigned
		APPLICANT: Sanghvi et al.	
		GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned
Sheet	4	of	6

PS	C42	KOOB et al., Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat. J Pharmacol Exp Ther. 1984 May;229(2):481-6.		
PS	C43	KOTAKE et al., Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica. 1989 Nov;19(11):1247-54.		
PS	C44	KROMER et al., Endogenous opioids, the enteric nervous system and gut motility. Dig Dis. 1990;8(6):361-73. Review.		
PS	C45	KROMER et al., The current status of opioid research on gastrointestinal motility. Life Sci. 1989;44(9):579-89. Review.		
PS	C46	LEANDER, A kappa opioid effect: increased urination in the rat. J Pharmacol Exp Ther. 1983 Jan;224(1):89-94.		
PS	C47	LITTLE, et al., Society for Neuroscience Abstracts, 27 (2); 2001, p. 2407		
PS	C48	LIVINGSTON et al., Postoperative ileus. Dig Dis Sci. 1990 Jan;35(1):121-32. Review.		
PS	C49	LYDON et al., ESA Free Paper Prize Competition. Eur J Anaesthesiol. 2001 Apr;18 Suppl 21:92.		
PS	C50	LYSLE et al., Modulation of immune status by a conditioned aversive stimulus: evidence for the involvement of endogenous opioids. Brain Behav Immun. 1992 Jun;6(2):179-88.		
PS	C51	MAGNAN et al., The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn Schmiedeberg Arch Pharmacol. 1982 Jun;319(3):197-205.		
PS	C52	MANARA, et al., Adv. Endog. Exog. Opioids, Poroc. Int. Narc. Res. Conf., 12th (1981), 402-4		
PS	C53	MANARA et al., The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol. 1985;25:249-73. Review.		
PS	C54	MICKLEY et al., Quaternary naltrexone reverses morphine-induced behaviors. Physiol Behav. 1985 Aug;35(2):249-53.		
PS	C55	MISRA et al., Intravenous kinetics and metabolism of [15,16-3H]naltrexonium methiodide in the rat. J Pharm Pharmacol. 1987 Mar;39(3):225-7.		
PS	C56	MOERMAN et al., Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences. Acta Anaesthesiol Belg. 1995;46(3-4):127-32.		
PS	C57	MOSS, et al., N. Engl. J. Med., (2002) 346 (6), 455		
PS	C58	MUCHA, Is the motivational effect of opiate withdrawal reflected by common somatic indices of precipitated withdrawal? A place conditioning study in the rat. Brain Res. 1987 Aug 25;418(2):214-20.		
PS	C59	MUCHA, Taste aversion involving central opioid antagonism is potentiated in morphine-dependent rats. Life Sci. 1989;45(8):671-8.		
PS	C60	MURPHY et al., Anesthesiology, Sept. (1999), 91 (3A) p. A349 (Abstract)		
PS	C61	MURPHY et al., Pharmacokinetic profile of epidurally administered methylnaltrexone, a novel peripheral opioid antagonist in a rabbit model. Br J Anaesth. 2001 Jan;86(1):120-2.		
PS	C62	MURPHY et al., American Society of Anesthesiologists 1999 annual meeting. Dallas, Texas, USA. October 9-13, 1999. Abstracts. Anesthesiology. 1999 Sep;91(3A Suppl):A349.		
PS	C63	MURPHY et al., Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology. 1997 Oct;87(4):765-70.		
PS	C64	MURPHY et al., Opioid antagonist modulation of ischaemia-induced ventricular arrhythmias: a peripheral mechanism. J Cardiovasc Pharmacol. 1999 Jan;33(1):122-5.		
PS	C65	NARANJO et al., Evidence for a central but not adrenal, opioid mediation in hypertension induced by brief isolation in the rat. Life Sci. 1986 May 26;38(21):1923-30.		
PS	C66	NELSON, Dissertation Abstracts International, (62/03-B), p. 1635 (Abstract)		
PS	C67	ODIO et al., Central but not peripheral opiate receptor blockade prolonged pituitary-adrenal responses to stress. Pharmacol Biochem Behav. 1990 Apr;35(4):963-9.		
PS	C68	OSINSKI et al., Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):251-9.		
PS	C69	PAPPAGALLO, Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001 Nov;182(5A Suppl):11S-18S. Review.		
PS	C70	POLAK et al., Enkephalin-like immunoreactivity in the human gastrointestinal tract. Lancet. 1977 May 7;1(8019):972-4.		
PS	C71	POWELL et al., Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther. 2002 Feb;300(2):588-96.		
PS	C72	QUOCK, et al, J. Bioelectr. (1986), 5(1), 35-46		

P. Spivack 5/27/07

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/821,809	ATTY. DOCKET NO.: P0453.70116US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: April 8, 2004	CONFIRMATION NO.: Not Yet Assigned
		APPLICANT: Sanghvi et al.	
		GROUP ART UNIT: Not Yet Assigned	EXAMINER: Not Yet Assigned
Sheet	5	of	6

PS	C73	QUOCK et al., Narcotic antagonist-induced hypotension in the spontaneously hypertensive rat. Life Sci. 1985 Sep 2;37(9):819-26.		
PS	C74	QUOCK et al., Narcotic antagonist potentiation of apomorphine drug effect: a stereospecific, centrally mediated drug action. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(3):239-43.		
PS	C75	RAMABADRAN, Effects of N-methylnaloxone and N-methylnaltrexone on nociception and precipitated abstinence in mice. Life Sci. 1982 Sep 20-27;31(12-13):1253-6.		
PS	C76	RIVIERE et al., Fedotozine reverses ileus induced by surgery or peritonitis: action at peripheral kappa-opioid receptors. Gastroenterology. 1993 Mar;104(3):724-31.		
PS	C77	ROBINSON et al., Oral naloxone in opioid-associated constipation. Lancet. 1991 Aug 31;338(8766):581-2.		
PS	C78	ROGER et al., Colonic motor responses in the pony: relevance of colonic stimulation by opiate antagonists. Am J Vet Res. 1985 Jan;46(1):31-5.		
PS	C79	RUSSELL et al., Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol. 1982 Mar 12;78(3):255-61.		
PS	C80	SCHAEFER et al., Effects of opioid antagonists and their quaternary derivatives on locomotor activity and fixed ratio responding for brain self-stimulation in rats. Pharmacol Biochem Behav. 1985 Nov;23(5):797-802.		
PS	C81	SCHANG et al., Beneficial effects of naloxone in a patient with intestinal pseudoobstruction. Am J Gastroenterol. 1985 Jun;80(6):407-11.		
PS	C82	SCHANG et al., How does morphine work on colonic motility? An electromyographic study in the human left and sigmoid colon. Life Sci. 1986 Feb 24;38(8):671-6.		
PS	C83	SCHILLER et al., Studies of the mechanism of the antidiarrheal effect of codeine. J Clin Invest. 1982 Nov;70(5):999-1008.		
PS	C84	SCHMIDHAMMER, et al., Helv. Chim. Acta (1994), Vol. 77, No. 6, p. 1585-9.		
PS	C85	SCHMIDHAMMER, et al., Helv. Chim. Acta. (1993) No. 1, p. 476-80.		
PS	C86	SCHOLZ, 2000, 63 (6) p. 103.		
PS	C87	SCHREIER et al., Central regulation of intestinal function: morphine withdrawal diarrhea. Proc West Pharmacol Soc. 1982;25:151-4.		
PS	C88	SOLVASON et al., Naltrexone blocks the expression of the conditioned elevation of natural killer cell activity in BALB/c mice. Brain Behav Immun. 1989 Sep;3(3):247-62.		
PS	C89	SWAN, et al., AIDS Research, NIDA Notes, (1995), 10(3), 1-6.		
PS	C90	SYKES, Oral naloxone in opioid-associated constipation. Lancet. 1991 Jun 15;337(8755):1475.		
PS	C91	TAGUCHI et al., Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001 Sep 27;345(13):935-40.		
PS	C92	THOMPSON et al., Opioid stimulation in the ventral tegmental area facilitates the onset of maternal behavior in rats. Brain Res. 1996 Dec 16;743(1-2):184-201.		
PS	C93	UKAI et al., Suppression of deprivation-induced water intake in the rat by opioid antagonists: central sites of action. Psychopharmacology (Berl). 1987;91(3):279-84.		
PS	C94	VALENTINO et al., Quaternary naltrexone: evidence for the central mediation of discriminative stimulus effects of narcotic agonists and antagonists. J Pharmacol Exp Ther. 1981 Jun;217(3):652-9.		
PS	C95	VALENTINO et al., Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci. 1983 Jun 20;32(25):2887-96.		
PS	C96	WALKER, et al., Psychopharmacology (1991), 104(2), p. 164-6.		
PS	C97	WARREN et al., Effects of quaternary naltrexone and chlordiazepoxide in squirrel monkeys with enhanced sensitivity to the behavioral effects of naltrexone. J Pharmacol Exp Ther. 1985 Nov;235(2):412-7.		
PS	C98	WILLETTE, et al., Res. Commun. Subst. Abuse (1983), 4(4), 325-37.		
PS	C99	YUAN et al., Drug Dev. Res. (2000) 50(2), 133-141.		
PS	C100	YUAN et al., Gastric effects of methylnaltrexone on mu, kappa, and delta opioid agonists induced brainstem unitary responses. Neuropharmacology. 1999 Mar;38(3):425-32.		
PS	C101	YUAN et al., Anesthesiology, Sept. (1995), 83 (3A), p A358 (Abstract)		
PS	C102	YUAN et al., Anesthesiology, Sept. (1995), 83 (3A), p A360 (Abstract)		
PS	C103	YUAN et al., Anesthesiology, Sept. (1999), 91 (3A) p. A973 (Abstract)		
PS	C104	YUAN et al., Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000 Apr;67(4):398-404.		
PS	C105	YUAN et al., The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 1997 Apr;61(4):467-75.		

Phyllis Spivack 5/27/07

<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/821,809		ATTY. DOCKET NO.: P0453.70116US01	
				FILING DATE: April 8, 2004		CONFIRMATION NO.: Not Yet Assigned	
				APPLICANT: Sanghvi et al.			
				GROUP ART UNIT: Not Yet Assigned		EXAMINER: Not Yet Assigned	
Sheet	6	of	6				

PS	C106	YUAN et al., Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther. 1996 Apr;59(4):469-75.		
PS	C107	YUAN, et al., Clinical Pharmacology & Therapeutics (1995) 57(2), p. 138		
PS	C108	YUAN et al., Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend. 1998 Oct 1;52(2):161-5.		
PS	C109	YUAN et al., Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur J Pharmacol. 1995 Mar 24;276(1-2):107-11.		
PS	C110	YUAN et al., Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther. 2002 Jan;300(1):118-23.		
PS	C111	YUAN et al., Oral methylnaltrexone for opioid-induced constipation. JAMA. 2000 Sep 20;284(11):1383-4.		
PS	C112	YUAN et al., Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000 Jan 19;283(3):367-72.		
PS	C113	YUAN et al., Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain. 1999 Dec;83(3):631-5.		
PS	C114	YUAN et al., Effects of methylnaltrexone on chronic opioid induced gut motility and transit time changes. Br J Anaesth. 1998;81(1):94.		
PS	C115	YUAN et al., Effects of methylnaltrexone on chronic opioid-induced gut motility and transit time changes. University of Leicester - Abstracts from the Eighth International Symposium on Pain, Anaesthesia and Endocrinology. 1997 September 18-19th.		
PS	C116	Oncology. 1996;10(12):1880.		

EXAMINER	Phyllis Spivack	DATE CONSIDERED	5/17/07
----------	-----------------	-----------------	---------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



FORM PTO 449/A and B (Modified)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/821,809      ATTY. DOCKET NO.: P0453.70116US01  
 FILING DATE: April 8, 2004      CONFIRMATION NO.: 9063  
 APPLICANT: Sanghvi et al.  
 GROUP ART UNIT: 1614      EXAMINER:

Sheet 1 of 3

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
PS	A30	4,311,833		Namikoshi, <i>et al.</i>	01-19-1982
	A31	4,377,568		Chopra, <i>et al.</i>	03-22-1983
	A32	4,385,078		Onda, <i>et al.</i>	05-24-1983
	A33	4,457,907		Porter, <i>et al.</i>	07-03-1984
	A34	4,462,839		McGinley, <i>et al.</i>	07-31-1984
	A35	4,518,433		McGinley, <i>et al.</i>	05-21-1985
	A36	4,556,552		Porter, <i>et al.</i>	12-03-1985
	A37	4,606,909		Bechgaard, <i>et al.</i>	08-19-1986
	A38	4,615,885		Nakagame, <i>et al.</i>	10-07-1986
	A39	4,670,287		Tsuji, <i>et al.</i>	06-02-1987
	A40	4,857,833		Sherman, <i>et al.</i>	08-15-1999
	A41	4,888,346		Bihari, <i>et al.</i>	12-19-1989
	A42	5,426,112		Zagon, <i>et al.</i>	06-20-1995
	A43	5,536,507		Abramowitz, <i>et al.</i>	07-16-1996
	A44	5,567,423		Ying, <i>et al.</i>	10-22-1996
	A45	5,591,433		Michael, <i>et al.</i>	01-07-1997
	A46	5,597,564		Ying, <i>et al.</i>	01-28-1997
	A47	5,609,871		Michael, <i>et al.</i>	03-11-1997
	A48	5,614,222		Kaplan, <i>et al.</i>	03-25-1997
	A49	5,626,875		Ballester Rodes, <i>et al.</i>	05-06-1997
	A50	5,629,001		Michael, <i>et al.</i>	05-13-1997
	A51	6,025,154		Li, <i>et al.</i>	02-15-2000
	A52	6,353,004	B1	Farrar, <i>et al.</i>	03-05-2002
	A53	6,469,030	B2	Farrer, <i>et al.</i>	10-22-2002
✓	A54	2001/0036951	A1	Farrar, <i>et al.</i>	11-01-2001

## FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
PS	B22	AU	758,416		Arch Development Corp.	07-03-1999	
	B23	CA	2,312,234		Arch Development Corp.	05-14-1999	
	B24	DE	3,780,819				
PS	B25	EP	1,047,726	A1	Quest International B.V.	07-22-1999	
PS	B26	WO	99/22737	A1	Arch Development Corp.	05-14-1999	
PS	B27	WO	04/043964	A2	Mallinckrodt	05-27-2004	

Phyllis Spinack 5/27/07



<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/821,809		ATTY. DOCKET NO.: P0453.70116US01	
				FILING DATE: April 8, 2004		CONFIRMATION NO.: 9063	
				APPLICANT: Sanghvi et al.			
				GROUP ART UNIT: 1614		EXAMINER: Not Yet Assigned	
Sheet	2	of	3				

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
PS	C117	ALTIER et al., Opioid receptors in the ventral tegmental area contribute to stress-induced analgesia in the formalin test for tonic pain. Brain Res. 1996 Apr 29;718(1-2):203-6.	
PS	C118	BAKER et al., Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice. J Pharmacol Exp Ther. 2002 Sep;302(3):1253-64.	
B	C119	BASILISCO et al., Oral naloxone antagonizes loperamide-induced delay of orocecal transit. Dig Dis Sci. 1987 Aug;32(8):829-32.	
PS	C120	BASILISCO et al., Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test. Gut. 1985 Jul;26(7):700-3.	
PS	C121	BOWEN et al., Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys. J Pharmacol Exp Ther. 2002 Jul;302(1):264-73.	
PS	C122	BOWEN et al., College on Problems of Drug Dependence 64th Annual Scientific Meeting. June 8-13, 2002. Quebec City, Quebec, Canada. Abstracts. Drug Alcohol Depend. 2002 May 1;66 Suppl 1:S1-220. Abstract No. 65.	
PS	C123	CARR et al., Naltrexone antagonizes the analgesic and immunosuppressive effects of morphine in mice. J Pharmacol Exp Ther. 1994 May;269(2):693-8.	
PS	C124	CHOI et al., Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage. 2002 Jul;24(1):71-90. Review.	
PS	C125	CHOI et al., Inhibition of chemokine-induced chemotaxis of monkey leukocytes by mu-opioid receptor agonists. In Vivo. 1999 Sep-Oct;13(5):389-96.	
PS	C126	DE PONTI et al., Methylnaltrexone Progenics. Curr Opin Investig Drugs. 2002 Apr;3(4):614-20. Review.	
PS	C127	FLORES et al., Mechanisms of morphine-induced immunosuppression: effect of acute morphine administration on lymphocyte trafficking. J Pharmacol Exp Ther. 1995 Mar;272(3):1246-51.	
PS	C128	GILES et al., Quaternary opiate antagonists lower blood pressure and inhibit leucine-enkephalin responses. Eur J Pharmacol. 1983 Nov 25;95(3-4):247-52.	
PS	C129	HO et al., Suppression of immunological functions in morphine addicted mice. NIDA Res Monogr. 1986;75:599-602.	
PS	C130	KEHLET et al., Review of postoperative ileus. Am J Surg. 2001 Nov;182(SA Suppl):3S-10S. Review.	
PS	C131	KOSTEN et al., Naltrexone and morphine alter the discrimination and plasma levels of ethanol. Behav Pharmacol. 1999 Feb;10(1):1-13.	
PS	C132	KOSTIC, CAS Abstract Document No. 127: 13345, 1997.	
PS	C133	LI et al., Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis. 2002 Jan 1;185(1):118-22. Epub 2001 Dec 14.	
PS	C134	MACK, Paralytic ileus: response to naloxone. Br J Surg. 1989 Oct;76(10):1101.	
PS	C135	NEMETH-LEFKOWITZ et al., Research communication in Substances of Abuse (1980) 1(2): 177-83.	
PS	C136	PHAM et al., Drugs of Abuse: Chemistry, Pharmacology, Immunology and AIDS; National Institute of Drug Research 96: Monograph Series. U.S. Department of Health and Human Services; 1990.	
PS	C137	QUANG-CONTAGREL et al., Long-term methadone treatment: effect on CD4+ lymphocyte counts and HIV-1 plasma RNA level in patients with HIV infection. Eur J Pain. 2001;5(4):415-20.	
PS	C138	SAKURADA et al., Differential antagonism of endomorphin-1 and endomorphin-2 supraspinal antinociception by naloxonazine and 3-methylnaltrexone. Peptides. 2002 May;23(5):895-901.	
PS	C139	SANDNER-KEISLING et al., Pharmacology of opioid inhibition to noxious uterine cervical distension. Anesthesiology. 2002 Oct;97(4):966-71.	
PS	C140	SHAVIT et al., Effects of a single administration of morphine or footshock stress on natural killer cell cytotoxicity. Brain Behav Immun. 1987 Dec;1(4):318-28.	
PS	C141	SOLDANI et al., Central and peripheral involvement of mu receptors in gastric secretory effects of opioids in the dog. Eur J Pharmacol. 1985 Nov 19;117(3):295-301.	
PS	C142	STEINBROOK et al., An opioid antagonist for postoperative ileus. N Engl J Med. 2001 Sep 27;345(13):988-9.	

P. Spivack 5/27/02



<b>FORM PTO-1449/A and B (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/821,809	ATTY. DOCKET NO.: P0453.70116US01
		FILING DATE: April 8, 2004	CONFIRMATION NO.: 9063
		APPLICANT: Sanghvi et al.	
		GROUP ART UNIT: 1614	EXAMINER: Not Yet Assigned
Sheet	3	of	3

PS	C143	WEI et al., Abstracts of the 2002 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Atlanta, Georgia, USA. March 24-27, 2002. Clin Pharmacol Ther. 2002 Feb;71(2):P1-136.		
PS	C144	WILMORE et al., Can we minimize the effects of opioids on the bowel and still achieve adequate pain control? Am J Surg. 2001 Nov;182(SA Suppl):1S-2S.		
PS	C145	WYBRAN et al., Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. J Immunol. 1979 Sep;123(3):1068-70.		
PS	C146	YUAN, Clinical Status of Methylnaltrexone, A New Agent to Prevent and Manage Opioid-Induced Side Effects. J Support Oncol. 2004 Mar/Apr: 2(2):111-22.		

EXAMINE R	<i>Phyllis Swinck</i>	DATE CONSIDERED	<i>5/27/07</i>
-----------	-----------------------	-----------------	----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

O T P E J C T I F E  
DEC 13 2004

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/821,809

ATTY. DOCKET NO.: P0453.70116US01

FILING DATE: April 8, 2004

CONFIRMATION NO.: 9063

APPLICANT: Sanghvi et al.

GROUP ART UNIT: 1614

EXAMINER: SPIVACK

Sheet

1

of

1

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
PS	A55	5,804,595		Portoghese, <i>et al.</i>	09-08-1998
PS	A56	5,866,154		Bahal, <i>et al.</i>	02-02-1999
PS	A57	2003-0022909	A1	Moss, <i>et al.</i>	01-30-2003
PS	A58	2003-0124086	A1	Bentley, <i>et al.</i>	07-03-2003
PS	A59	2003-0191147	A1	Sherman, <i>et al.</i>	10-09-2003

## FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
PS	B28	CA	2,064,373		Lilly (Eli) and Company	09-30-1992	
PS	B29	EP	506,468	A1	Eli Lilly and Company	09-30-1992	
PS	B30	EP	643,967	A2	Euro Celtique S.A.	03-22-1995	
PS	B31	WO	01/32180	A2	Rodeva Limited	05-10-2001	
PS	B32	WO	02/098422	A1	University of Chicago	12-12-2002	
PS	B33	WO	03/032990	A2	Shearwater Corporation	04-24-2003	
PS	B34	WO	2004/014291	A2	Moss	02-19-2004	

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
PS	C147	FARTHING et al., New drugs in the management of the irritable bowel syndrome. Drugs. 1998 Jul;56(1):11-21. Review.	
PS	C148	FINGL et al., Chapter 43: Laxatives and cathartics. In Pharmacological Basis of Therapeutics. 1980: 1002-5.	
PS	C149	SCHUBERT-ZSILAVECZ et al., Das reizdarmsyndrom irritable bowel syndrome. Deutsche apotheke zeitung. 2002 Aug 22; 142(34): 40-9.	Yes
PS	C150	TALLEY et al., Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol. 2003 Apr;98(4):750-8. Review.	
PS	C151	THOMPSON et al., Laxatives: clinical pharmacology and rational use. Drugs. 1980 Jan;19(1):49-58. Review.	

EXAMINER:

Phyllis Spivack

DATE CONSIDERED:

5/27/07

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICATION NO.: 10/821,809

ATTY. DOCKET NO.: P0453.70116US01

FILING DATE: April 8, 2004

CONFIRMATION NO.: 9063

APPLICANT: Sanghvi et al.

GROUP ART UNIT: 1614

EXAMINER: Phyllis G. Spivack

Sheet 1 of 4

FEB 23 2007

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
PS		4,322,426		Hermann et al.	03-30-1982
		4,965,269		Brändström et al.	10-23-1990
		5,159,081		Cantrell et al.	10-27-1992
		5,202,159		Chen et al.	04-13-1993
		5,391,372		Campbell	02-21-1995
		5,614,219		Wunderlich et al.	03-25-1997
		5,656,290		Kelm et al.	08-12-1997
		5,981,185		Matson et al.	11-09-1999
		6,455,537		Cooper	09-24-2002
		6,986,901		Meisel et al.	01-17-2006
		2002-0064771	A1	Zhong et al.	05-30-2002
		2003-0026801	A1	Weiner et al.	02-06-2003
		2003-0065003	A1	Foss et al.	04-03-2003
		2003-0187010	A1	Foss et al.	10-02-2003
		2004-0162306	A1	Foss et al.	08-19-2004
		2004-0162307	A1	Foss et al.	08-19-2004
		2004-0162308	A1	Foss et al.	08-19-2004
		2004-0167147	A1	Foss et al.	08-26-2004
		2004-0167148	A1	Foss et al.	08-26-2004
		2004-0259899	A1	Sanghvi et al.	12-23-2004
		2004-0266806	A1	Sanghvi et al.	12-30-2004
		2005-0004155	A1	Boyd et al.	01-06-2005
		2005-0048117	A1	Foss et al.	03-03-2005
		2005-0124885	A1	Abend et al.	06-09-2005
		2006-0205753	A1	Israel	09-14-2006

## FOREIGN PATENT DOCUMENTS

Examiner's Initials <sup>#</sup>	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
PS		DE	196 51 551	A1	Klinge Pharm GmbH	06-18-1998	Y-Abstract
		EP	0 289 070		Duphair International Research B.V.	11-02-1988	

EXAMINER:

P. Spivack

DATE CONSIDERED:

5/27/07

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/821,809		ATTY. DOCKET NO.: P0453.70116US01	
				FILING DATE: April 8, 2004		CONFIRMATION NO.: 9063	
				APPLICANT: Sanghvi et al.			
				GROUP ART UNIT: 1614		EXAMINER: Phyllis G. Spivack	
Sheet	2	of	4				

PS		WO	96/14058	A1	Euroceltique, S.A.	05-17-1996	
PS		WO	2004/091623	A1	Progenics Pharmaceuticals, Inc.	10-28-2004	

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		<del>[No Author Listed] Ion Channels and Genetic Diseases, Chapter 1.</del>	
PS		Remington's Pharmaceutical Sciences, 15 <sup>th</sup> Edition, 1975:1614-5. 1975	
PS		Progenics initiates second phase 3 clinical trial of methylnaltrexone in opioid-induced constipation. Press Release. Progenics Pharmaceuticals, Inc. January 13, 2004.	
PS		Progenics achieves enrollment target in pivotal phase 3 clinical trial of methylnaltrexone for opioid-induced constipation. Press Release. Progenics Pharmaceuticals, Inc. December 3, 2004.	
PS		Progenics announces positive top-line results from pivotal phase 3 clinical trial of MNTX in opioid-induced constipation. Press Release. Progenics Pharmaceuticals, Inc. March 10, 2005.	
PS		AUNG et al., Methylnaltrexone prevents morphine-induced kaolin intake in the rat. Life Sci. 2004 Apr 16;74(22):2685-91.	
PS		BROWN et al., Techniques for mechanical stimulation of cells in vitro: a review. J Biomech. 2000 Jan;33(1):3-14.	
PS		EGAN et al., Prospective pharmacokinetic and pharmacodynamic validation of propofol's context sensitive T1/2. Anesthesiology. 1999 Sep;91(3A): Abstract A347.	
PS		FOSS et al., The efficacy of oral methylnaltrexone in decreasing the subjective effects of IV morphine. Anesth Analg. 1997;84. Abstract S484.	
PS		FOSS et al., Enteric-coated methylnaltrexone prevents opioid-induced oral-cecal transit delay in humans. Anesth Analg. 2000;90. Abstract S409.	
PS		FOSS et al., Subcutaneous methylnaltrexone reduces morphine-induced subjective effects in humans. Anesthesiology. 2001;95. Abstract A-817.	
PS		FRANCE et al., Morphine, saline and naltrexone discrimination in morphine-treated pigeons. J Pharm and Exper Ther. 1987;242:195-202.	
PS		FUNKE et al., A proton and carbon-13 nuclear magnetic resonance study of three quaternary salts of naloxone and oxymorphone. J Chem Soc. 1986:735-8.	
PS		GUTSTEIN et al., Role of inositol 1,4,5-trisphosphate receptors in regulating apoptotic signaling and heart failure. Heart Vessels. 1997;Suppl 12:53-7.	
PS		HICKS et al., Differential effects of the novel non-peptidic opioid 4-tyrosylamido-6-benzyl-1,2,3,4 tetrahydroquinoline (CGPM-9) on in vitro rat T lymphocyte and macrophage functions. Life Sci. 2001 May 4;68(24):2685-94.	
PS		HIROTA et al., Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999 Apr 16;97(2):189-98.	
PS		HO et al., Beta-endorphin: peripheral opioid activity of homologues from six species. Int J Pept Protein Res. 1987 Apr;29(4):521-4.	

EXAMINER: Phyllis Spivack	DATE CONSIDERED: 5/27/07
---------------------------	--------------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/821,809		ATTY. DOCKET NO.: P0453.70116US01	
				FILING DATE: April 8, 2004		CONFIRMATION NO.: 9063	
				APPLICANT: Sanghvi et al.			
				GROUP ART UNIT: 1614		EXAMINER: Phyllis G. Spivack	
Sheet	3	of	4				

PS	HO et al., Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J Pharmacol Exp Ther. 2003 Dec;307(3):1158-62.	
PS	HOFMANN et al., Hypocalcemia during restraint stress in rats. Indication that gastric ulcer prophylaxis by exogenous calcium interferes with calcitonin release. Res Exp Med (Berl). 1979 May 30;175(2):159-68.	
PS	HUSSAIN et al., Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach. J Pharm Sci. 1987 May;76(5):356-8.	
PS	HUSSAIN et al., Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs. Pharm Res. 1988 Feb;5(2):113-5.	
PS	IORIO et al., Narcotic agonist/antagonist properties of quaternary diastereoisomers derived from oxymorphone and naloxone. Eur J Med Chem. 1984;19(4):301-3.	
PS	LOPEZ et al., Demonstration of long-lasting blockade of experimental ileus in rats by an opioid k-agonist. Gastroenterology. 1995;108(4):A640. Abstract.	
PS	MCCARTHY et al., Preliminary studies on the use of plasma $\beta$ -endorphin in horses as an indicator of stress and pain. J Equine Vet Sci. 1993;13(4):216-9.	
PS	MIEDEMA et al., Methods for decreasing postoperative gut dysmotility. Lancet Oncol. 2003 Jun;4(6):365-72.	
PS	MOSS et al., Methylnaltrexone prevents morphine-induced CCR5 receptor expression. Anesthesiology. 2003;99. Abstract A-961.	
PS	PAPAPETROPOULOS et al., Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro. Am J Pathol. 1997 May;150(5):1835-44.	
PS	RESNICK et al., Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part I. Am J Gastroenterol. 1997 May;92(5):751-62.	
PS	RESNICK et al., Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part II. Am J Gastroenterol. 1997 Jun;92(6):934-40.	
PS	STEPHENSON et al., Methylnaltrexone reverses opioid-induced constipation. Lancet Oncol. 2002 Apr;3(4):202.	
PS	THOMAS et al., Amelioration of peripheral side effects of opioids: clinical experience with methylnaltrexone (MNTX). Proc World Congr Anesth. 2004:107.	
PS	TOMIYASU et al., Analysis of intercostal nerve damage associated with chronic post-thoracotomy pain. Anesthesiology. 2001;95. Abstract A-964.	
PS	WEI et al., Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? Biochem Pharmacol. 2003 Jun 1;65(11):1761-6.	
PS	WEI et al., Pharmacokinetics of subcutaneous methylnaltrexone: different route administration comparison. 2001. ASA Annual Meeting Abstracts. October 14-18, 2001. Chicago, IL. Abstract A-962.	
PS	YUAN et al., Gut and brain effects of American ginseng root on brainstem neuronal activities in rats. Amer J Chin Med. 1998; 26: 47-55.	
PS	YUAN et al., Methylnaltrexone (MNTX) for chronic opioid-induced constipation. 2002 ASCO Annual Meeting. Proc Am Soc Clin Oncol. 2002;21:376a. Abstract 1501.	
PS	YUAN et al., Safety and tolerance of oral methylnaltrexone in healthy volunteers. Anesth Analg. 1997;84:S1-599. Abstract S574.	

EXAMINER:	DATE CONSIDERED:
Phyllis Spivack	5/27/07

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/821,809		ATTY. DOCKET NO.: P0453.70116US01	
				FILING DATE: April 8, 2004		CONFIRMATION NO.: 9063	
				APPLICANT: Sanghvi et al.			
				GROUP ART UNIT: 1614		EXAMINER: Phyllis G. Spivack	
Sheet	4	of	4				

PS		YUAN et al., Methylnaltrexone changes gut motility and transit time in chronic methadone-maintained subjects. <i>Anesth Analg.</i> 1999;88: S1-424. Abstract S404.	
PS		YUAN et al., Antagonism of chronic opioid-induced gut effects. <i>Anesth Analg.</i> 2000;90:S1-523. Abstract S479.	
PS		YUAN et al., Pharmacokinetics of intravenous vs. oral methylnaltrexone: evidence for direct gut effects. <i>Anesth Analg.</i> 2001;92: S1-363. Abstract S274.	
PS		YUAN et al., Oral methylnaltrexone reverses morphine-induced changes in gastrointestinal motility. <i>Anesthesiology.</i> 1996 Sep;85(3A). Abstract A335.	
PS		YUAN et al., Oral methylnaltrexone reverses chronic opioid-induced constipation. <i>Anesthesiology.</i> 2000 Sep;93(3A). Abstract A-872.	
PS		YUAN et al., Subcutaneous methylnaltrexone prevents morphine-induced delay in gut transit time: a clinical trial. <i>Anesthesiology.</i> 2001;95. Abstract A-963.	
PS		YUAN et al., Methylnaltrexone prevents morphine-induced kaolin intake in the rat. <i>Anesthesiology.</i> 2003;99. Abstract A-922.	
PS		YUAN et al., Dose-related effects of oral acetaminophen on cold-induced pain: a double-blind, randomized, placebo-controlled trial. <i>Clin Pharmacol Ther.</i> 1998 Mar;63(3):379-83.	
PS		YUAN et al., Gastric effects of mu-, delta- and kappa-opioid receptor agonists on brainstem unitary responses in the neonatal rat. <i>Eur J Pharmacol.</i> 1996 Oct 24;314(1-2):27-32.	
PS		YUAN et al., Effects of low-dose morphine on gastric emptying in healthy volunteers. <i>J Clin Pharmacol.</i> 1998 Nov;38(11):1017-20.	
PS		YUAN et al., Gut motility and transit changes in patients receiving long-term methadone maintenance. <i>J Clin Pharmacol.</i> 1998 Oct;38(10):931-5.	
PS		YUAN et al., Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. <i>J Clin Pharmacol.</i> 2005 May;45(5):538-46.	
PS		YUAN et al., Antagonism of gastrointestinal opioid effects. <i>Reg Anesth Pain Med.</i> 2000 Nov-Dec;25(6):639-42.	
PS		YUAN et al., Methylnaltrexone reduces oral-cecal transit time in humans. <i>Dig Dis Week Abstr.</i> 2003:A-578. Abstract T1840.	
PS		YUAN et al., Opioid analgesia without gut side effects: effects of methylnaltrexone as a novel peripheral opioid antagonist. <i>Assoc Univ Anesth Abst.</i> 2003: PD2.	
PS		YUAN et al., Pain control with side effects: clinical studies on methylnaltrexone as a novel peripheral opioid antagonist. 7 <sup>th</sup> America-Japan Anesth Congr. Yamanashi, Japan. 2002:41.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	Phyllis Spivack	DATE CONSIDERED:	5/27/07
-----------	-----------------	------------------	---------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.